Published in Fitness and Wellness Business Week, August 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at SPEEDEL Pharma.
Report 1: Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the successful completion of a Phase IIa proof-of-concept clinical trial with SPP635 for the treatment of hypertension. Based on these positive results, the company is to continue developing SPP635 in Phase II in a special population of diabetic patients with mild-to-moderate hypertension. This compound is the first of a next...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.